Karyopharm to Announce Q2 2024 Financial Results on August 6

NEWTON, Mass., July 31, 2024 – Karyopharm Therapeutics Inc., a notable pharmaceutical company specializing in innovative cancer treatments, is set to disclose its financial performance for the second quarter of 2024. The announcement is scheduled for Tuesday, August 6, 2024. Accompanying the financial disclosure, the company's management will hold a conference call and an audio webcast at 8:00 a.m. ET on the same day to discuss the results and provide updates on the company's recent activities.

Interested participants can join the conference call by dialing (800) 836-8184 for local calls or (646) 357-8785 for international calls at least ten minutes before the start time. They should request to be connected to the Karyopharm Therapeutics call. The event will be supplemented with a live audio webcast, including slides, accessible under the "Events & Presentations" section in the Investor area of Karyopharm's website. Additionally, a recorded version of the webcast will be available on the website approximately two hours post-event.

Karyopharm Therapeutics Overview

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical firm, traded on Nasdaq under the ticker KPTI. The company is committed to developing cutting-edge cancer treatments, driven by a profound respect for the resilience and bravery of cancer patients. Since its inception, Karyopharm has been at the forefront of creating oral treatments that address the dysregulation of nuclear export, a critical factor in the development of cancer.

The company's flagship product, XPOVIO® (selinexor), is an innovative oral exportin 1 (XPO1) inhibitor. XPOVIO® has secured approval in the United States and is marketed by Karyopharm for three oncology indications. Furthermore, it has obtained regulatory approvals for various indications in several international territories, including Europe, the United Kingdom (as NEXPOVIO®), and China.

The firm maintains a focused pipeline aimed at addressing multiple types of cancer with significant unmet medical needs. These include multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!